Bladder Cancer

Newly Approved Drug Durvalumab (Trademark Imfinzi)

Newly Approved Drug Durvalumab (Trademark Imfinzi)

Durvalumab (Trademark Imfinzi) Bladder cancer is the 9th most common type of cancer in the world with 430,000 new cases alone diagnosed in 2012 according to World Cancer Research Fund International. Previously patients with bladder cancer, urothelial carcinoma, (UC) had two main options: standard platinum containing chemotherapy, and… Spread the love          

Cancer Research UK and Astex Team Up to Test DNMT Inhibitor

Cancer Research UK and Astex Team Up to Test DNMT Inhibitor

Cancer Research UK (CRUK) in conjunction with Astex has begun a Phase I/II Trial to measure the success of a DNA Methyltransferase (DNMT) inhibitor can halt the progress of bladder cancer proving resistant to chemotherapy.

Rethinking Radical Cystectomy for Patients with Muscle Invasive Bladder Cancer

Rethinking Radical Cystectomy for Patients with Muscle Invasive Bladder Cancer

Is it time for urologist to begin to rethink the radical cystectomy, and begin to explore trimodality therapy? Maybe, maybe not, depends on who you ask. Let’s go over a few things first before we jump right in though:

Heating chemo drug before using it as treatment for bladder cancer can great increase its effectiveness

Heating chemo drug before using it as treatment for bladder cancer can great increase its effectiveness

According to research published in the International Journal of Hypothermia scientists have discovered that by heating the chemo drug Mitomycin-C before administering it to patients who were undergoing chemo to treat bladder cancer.